Expertise in
3
conditions

Olivier J. Capitain

Nantes, FR 
Expertise in
3
conditions
Nantes, FR 

Overview

Olivier Capitain practices practicing medicine in Nantes, France.

Mr. Capitain is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Dihydropyrimidine Dehydrogenase Deficiency, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Cancer, Anal Cancer, and Laryngectomy.

He is actively involved in clinical research, co-authoring 39 peer reviewed articles and participating in 10 clinical trials.

Gender

Male

Locations

Nantes, France
Other Locations
Angers, France
Rene, France
Saint Herblain, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival
Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival
Enrollment Status: Completed
Publish Date: April 17, 2026
Intervention Type: Other
Study Phase: Phase 4
Phase-2 Study Evaluating Overall Response Rate (Efficacy) and Autonomy Daily Living Preservation (Tolerance) of FOLFIRINOX Pharmacogenetic Dose Adjusted, in Elderly Patients (70 yo. or Older) With a Metastatic Pancreatic Adenocarcinoma.
Phase-2 Study Evaluating Overall Response Rate (Efficacy) and Autonomy Daily Living Preservation (Tolerance) of FOLFIRINOX Pharmacogenetic Dose Adjusted, in Elderly Patients (70 yo. or Older) With a Metastatic Pancreatic Adenocarcinoma.
Enrollment Status: Completed
Publish Date: April 15, 2026
Intervention Type: Drug
Study Drugs: Oxaliplatine, Folinic acid, Irinotecan, 5-FU
Study Phase: Phase 2
Phase II Randomized Study Measuring the Interest of Pursuing or Not the CT for Non-progressive Patients With Metastatic Esophageal Squamous-cell Cancer After 6 Weeks of LV5FU2-paclitaxel Given After a 1st Line Fluoropyrimidine/Pt Salt CT
Phase II Randomized Study Measuring the Interest of Pursuing or Not the CT for Non-progressive Patients With Metastatic Esophageal Squamous-cell Cancer After 6 Weeks of LV5FU2-paclitaxel Given After a 1st Line Fluoropyrimidine/Pt Salt CT
Enrollment Status: Terminated
Publish Date: March 18, 2026
Intervention Type: Drug
Study Drug: Chemotherapy
Study Phase: Phase 2
Phase II Randomized Trial Evaluting Aflibercept Associated With LV5FU2 Regimen as First Line Treatment of Non-resectalbe Metastatic Colorectal Cancers
Phase II Randomized Trial Evaluting Aflibercept Associated With LV5FU2 Regimen as First Line Treatment of Non-resectalbe Metastatic Colorectal Cancers
Enrollment Status: Completed
Publish Date: July 10, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase III Trial Comparing Chemotherapy With Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma
A Randomized Phase III Trial Comparing Chemotherapy With Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma
Enrollment Status: Completed
Publish Date: January 09, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Folinic Acid, 5-Fluoro-uracil, Oxaliplatin, Irinotecan, L-folinic
Study Phase: Phase 3
A Safety Study of Nivolumab in Patients With Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)
A Safety Study of Nivolumab in Patients With Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Completed
Publish Date: January 18, 2023
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours
Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours
Enrollment Status: Completed
Publish Date: February 24, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02
A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02
Enrollment Status: Completed
Publish Date: June 01, 2021
Intervention Type: Drug
Study Drug: Afatinib
Study Phase: Phase 3
Pre-emptive Cycline Treatment on Cetuximab-induced Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With an Intensified FOLFIRI.
Pre-emptive Cycline Treatment on Cetuximab-induced Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With an Intensified FOLFIRI.
Enrollment Status: Terminated
Publish Date: March 25, 2020
Intervention Type: Drug
Study Phase: Not Applicable
The Medical-financial Evaluation of Pre-therapeutic Screening by a Joint Phenotypic-pharmacogenetic Approach for Metabolic Fluoropyrimidine Enzyme Deficiency in Terms of Serious Toxicity Risk Prevention : a Multicentric Case Study
The Medical-financial Evaluation of Pre-therapeutic Screening by a Joint Phenotypic-pharmacogenetic Approach for Metabolic Fluoropyrimidine Enzyme Deficiency in Terms of Serious Toxicity Risk Prevention : a Multicentric Case Study
Enrollment Status: Terminated
Publish Date: March 25, 2020
Intervention Type: Genetic
Study Phase: Not Applicable
View 9 Less Clinical Trials

39 Total Publications

Hybrid ReGex and Natural Language Inference Model as a Zero-Shot Classifier for Extracting Data From Medical Reports.
Hybrid ReGex and Natural Language Inference Model as a Zero-Shot Classifier for Extracting Data From Medical Reports.
Journal: JCO clinical cancer informatics
Published: September 22, 2025

Frequently Asked Questions about Olivier J. Capitain

Is Olivier J. Capitain a top-rated expert for Dihydropyrimidine Dehydrogenase Deficiency?

MediFind is an objective health platform that identifies experts based on real-world data. Olivier J. Capitain is classified as an Elite expert for Dihydropyrimidine Dehydrogenase Deficiency, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Olivier J. Capitain participate in research or clinical trials?

Yes. Olivier J. Capitain has published 39 articles and abstracts on conditions like Dihydropyrimidine Dehydrogenase Deficiency. You can view a list of Olivier J. Capitain's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Capitain's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile